Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing. The post Novartis Tries Again in Huntington’s, Putting Up…
The answer to this question depends, not only on how well AI tools work, but also on how AI technologies are regulated by the FDA. Scott Gottlieb has some thoughts on preferred regulatory approaches in his recent article in JAMA Health Forum. Artificial intelligence tools with advanced analytical capabilities used in clinical practice, especially tools…
We should use AI to develop recommendations for breast cancer screening protocols based on quantified risk, factoring in family history, ethnicity, genetics, and density, et al. – and then support the use of powerful new imaging AI technologies for those cases that demand a deeper look. The post Navigating the Breast Cancer Screening Debate: The…
Sprinter Health’s $55 million Series B round was led by General Catalyst and included participation from Andreessen Horowitz (a16z) Bio + Health, the Regents of the University of California, Google Ventures and Accel. The post Sprinter Health Raises $55M to Expand Home Health Services for Health Plans appeared first on MedCity News.
The assisted living facility in Edina, Minnesota, where Jean Peters and her siblings moved their mother in 2011, looked lovely. “But then you start uncovering things,” Peters said. Her mother, Jackie Hourigan, widowed and developing memory problems at 82, too often was still in bed when her children came to see her midmorning. “She wasn’t…
Neurotech Pharmaceuticals’ surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). It’s the first therapy for this rare retinal degeneration disorder. The post Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder appeared first on MedCity News.
How best can you design an outcomes based agreement (OBA)? What are the key factors to consider? Project IDEATE is a “cross-disciplinary collaboration between National Health Service (NHS) Wales, industry and academia” with the aim to develop and refine OBA models. What were the key factors IDEATE considered for an OBA? Feasibility: Identify parameters to…
To effectively address health disparities, organizations must implement health equity strategies that target systemic barriers and root causes. Here are strategies that can help drive comprehensive, system-wide change. The post How Health Systems Can Bridge Gaps in Health Equity appeared first on MedCity News.
Ultimately, the benefits of establishing a data-driven culture reach far beyond improved analytics. It enables a smarter, faster, and more inclusive decision-making process that leads to better care for patients, reduced provider burnout, and stronger financial resilience The post The Benefits of Establishing a Data-driven Culture in Healthcare appeared first on MedCity News.
CMS launched a new initiative to promote better data interoperability and digital health innovation. As part of the effort, more than 60 organizations pledged to build patient-facing apps and support secure data sharing — including OpenAI, Amazon, Apple, Cleveland Clinic and Providence. The post 60+ Companies Join CMS’ New Initiative for Data Interoperability & Patient-Facing…